The US Food and Drug Administration approved Zycubo (copper histidinate) injection on January 13, 2026, making it the first approved treatment for Menkes disease, a rare inherited copper-transport disorder of childhood, according to an FDA announcement. Until now, care for affected children was supportive only.
Newspaper Daily publishes information, not medical advice. The outlet reports on regulatory actions and research findings and does not provide diagnosis or treatment guidance.
Why the approval matters
Menkes disease is caused by genetic changes that impair the body's ability to move copper where it is needed. Infants with the condition typically decline over the first years of life, and no disease-specific therapy had ever cleared the FDA review process. The agency described Zycubo as the first bioavailable copper replacement therapy; because it is given by injection, it bypasses the impaired absorption in the gut that makes oral copper supplements ineffective in this condition, the agency said.
The therapy was developed by Cyprium Therapeutics and will be marketed by Sentynl Therapeutics, according to company announcements made around the approval.
Related stories: FDA Approves Lumvoa for Thyroid Eye Disease, Including Chronic Cases · FDA Approves Zidesamtinib for ROS1-Positive Lung Cancer After Progression.
What this finding can and cannot show
The approval establishes that the regulator judged the therapy's evidence sufficient for a condition with no prior approved option. It does not establish that every child will respond, how much developmental impact early treatment can prevent, or how the therapy compares with any other approach, because no approved comparator exists. Families and clinicians will need to weigh treatment burden, monitoring requirements, and the stage of disease at which therapy begins, questions that the approval itself does not answer.
When to talk to a clinician
Parents of children with a suspected or confirmed Menkes diagnosis should discuss timing of referral with a metabolic or genetic specialist. Regulators generally review rare-disease therapies under accelerated evidence standards, and post-approval data collection continues after launch.
What happens next
Availability, dosing protocols, and insurance coverage will be worked out between the marketer and treatment centers in the months after approval. Because the condition is rare, treatment is expected to concentrate at centers experienced in pediatric metabolic disease.